Next Article in Journal
Development and Successful Validation of Simple and Fast TLC Spot Tests for Determination of Kryptofix® 2.2.2 and Tetrabutylammonium in 18F-Labeled Radiopharmaceuticals
Next Article in Special Issue
Part Two: Evaluation of N-methylbupropion as a Potential Bupropion Prodrug
Previous Article in Journal
Human Antimicrobial Peptides and Proteins
Previous Article in Special Issue
Amino Acid Prodrugs: An Approach to Improve the Absorption of HIV-1 Protease Inhibitor, Lopinavir
Article Menu

Export Article

Open AccessArticle
Pharmaceuticals 2014, 7(5), 595-620;

Synthesis, Screening and Pharmacokinetic Evaluation of Potential Prodrugs of Bupropion. Part One: In Vitro Development

School of Pharmacy and Pharmaceutical Sciences, University of Dublin, Trinity College, Dublin 1, Ireland
Author to whom correspondence should be addressed.
Received: 13 March 2014 / Revised: 30 April 2014 / Accepted: 8 May 2014 / Published: 14 May 2014
(This article belongs to the Special Issue Prodrugs: from Design to Clinic)
Full-Text   |   PDF [653 KB, uploaded 14 May 2014]   |  


In general, prodrugs are developed to circumvent deficiencies associated with the absorption, distribution, metabolism, excretion or toxicological (ADMET) profile associated with the active drug. In our study, we select bupropion, a drug with broad pharmacology incorporating dopaminergic, noradrenergic, nicotinic and cytokine modulation properties, but which is rapidly metabolized in vivo. we exploited its carbonyl and secondary amine functionality to facilitate the synthesis of bioprecursor prodrug forms with the sole objective of identifying analogues with enhanced properties over bupropion. A range of analogues were synthesized, ranging from N-methyl, N-benzyl, oximes, enol acetate and ether forms to examples where both functional groups were utilized to form oxadiazine, oxadiazinone, oxazolone and acetylated derivatives. we then developed an in vitro metabolic screen to simulate the human oral delivery route for these analogues. The selection of media in the screens contained a variety of pH, enzymatic and co-factor systems which mimic metabolic in vivo environments that drugs encounter when delivered orally. By coupling our in vitro screening tool to a selective hyphenated technique such as LC-MS, we were able to quickly select potential prodrugs for further in vitro and in vivo development. From the data generated, the N-alkylated bupropion analogues were shown to have the highest potential to act as bioprecursor prodrugs of bupropion. View Full-Text
Keywords: bupropion; bioprecursor; prodrug; microsomes; plasma; in vitro; metabolism bupropion; bioprecursor; prodrug; microsomes; plasma; in vitro; metabolism

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

O'Byrne, P.M.; Williams, R.; Walsh, J.J.; Gilmer, J.F. Synthesis, Screening and Pharmacokinetic Evaluation of Potential Prodrugs of Bupropion. Part One: In Vitro Development. Pharmaceuticals 2014, 7, 595-620.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top